SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Organisation › Details

Cullinan Oncology LLC

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, the company’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model. Cullinan is backed by the UBS Oncology Impact Fund (OIF) managed by MPM Capital, a worldwide leader in oncology investing, and F2 Ventures. *


Period Start 2017-10-03 existent
  Group Cullinan Oncology (Group)
Product Industry antibody cancer drug
Persons Person Hughes, Owen (MPM Capitap 201710 Managing Director + Cullinan Oncology 201710– CEO before Intarcia + 16y at Wall Street)
  Person 2 Bäuerle, Patrick (MPM Capital 201710 Managing Director formerly Micromet)
  City n. a. 
    Address record changed: 2018-02-27
Basic data Employees n. a.
    * Document for �About Section�: 
Record changed: 2018-10-31


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Cullinan Oncology (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 600x60px

» top